NKGen Biotech (NKGN) Competitors $0.31 +0.02 (+6.83%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends NKGN vs. DYAI, GANX, ACHL, AFMD, BLRX, ATNM, OCX, RVPH, OMGA, and VRCAShould you be buying NKGen Biotech stock or one of its competitors? The main competitors of NKGen Biotech include Dyadic International (DYAI), Gain Therapeutics (GANX), Achilles Therapeutics (ACHL), Affimed (AFMD), BioLineRx (BLRX), Actinium Pharmaceuticals (ATNM), OncoCyte (OCX), Reviva Pharmaceuticals (RVPH), Omega Therapeutics (OMGA), and Verrica Pharmaceuticals (VRCA). These companies are all part of the "pharmaceutical products" industry. NKGen Biotech vs. Dyadic International Gain Therapeutics Achilles Therapeutics Affimed BioLineRx Actinium Pharmaceuticals OncoCyte Reviva Pharmaceuticals Omega Therapeutics Verrica Pharmaceuticals Dyadic International (NASDAQ:DYAI) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, community ranking, analyst recommendations and earnings. Which has more risk & volatility, DYAI or NKGN? Dyadic International has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500. Does the media prefer DYAI or NKGN? In the previous week, Dyadic International had 9 more articles in the media than NKGen Biotech. MarketBeat recorded 9 mentions for Dyadic International and 0 mentions for NKGen Biotech. Dyadic International's average media sentiment score of 0.85 beat NKGen Biotech's score of 0.00 indicating that Dyadic International is being referred to more favorably in the media. Company Overall Sentiment Dyadic International Positive NKGen Biotech Neutral Does the MarketBeat Community favor DYAI or NKGN? Dyadic International received 161 more outperform votes than NKGen Biotech when rated by MarketBeat users. CompanyUnderperformOutperformDyadic InternationalOutperform Votes16164.40% Underperform Votes8935.60% NKGen BiotechN/AN/A Do analysts prefer DYAI or NKGN? Dyadic International presently has a consensus target price of $6.00, suggesting a potential upside of 302.68%. Given Dyadic International's stronger consensus rating and higher probable upside, research analysts plainly believe Dyadic International is more favorable than NKGen Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dyadic International 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00NKGen Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has better earnings & valuation, DYAI or NKGN? Dyadic International has higher revenue and earnings than NKGen Biotech. Dyadic International is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDyadic International$2.90M15.20-$6.80M-$0.23-6.48NKGen Biotech$80K138.35-$82.94M-$5.08-0.06 Is DYAI or NKGN more profitable? NKGen Biotech has a net margin of 0.00% compared to Dyadic International's net margin of -188.09%. NKGen Biotech's return on equity of 0.00% beat Dyadic International's return on equity.Company Net Margins Return on Equity Return on Assets Dyadic International-188.09% -149.16% -59.81% NKGen Biotech N/A N/A -479.36% Do institutionals and insiders believe in DYAI or NKGN? 28.0% of Dyadic International shares are held by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are held by institutional investors. 28.8% of Dyadic International shares are held by company insiders. Comparatively, 74.7% of NKGen Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryDyadic International beats NKGen Biotech on 11 of the 17 factors compared between the two stocks. Ad Wyatt Investment ResearchMy #1 Pre IPO Trade for 2025 – NAME and TICKEROne tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...The Next SpaceX Pre-IPO Get NKGen Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for NKGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NKGN vs. The Competition Export to ExcelMetricNKGen BiotechBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$11.07M$2.93B$5.01B$19.85BDividend YieldN/A1.89%5.16%3.52%P/E Ratio-0.0645.25134.3742.73Price / Sales138.35360.241,158.6819.27Price / CashN/A160.0933.5317.86Price / Book-0.123.734.675.52Net Income-$82.94M-$41.63M$119.07M$986.45M7 Day Performance12.96%-4.73%-1.83%0.45%1 Month Performance-30.63%-6.53%-3.62%1.05%1 Year Performance-88.78%25.63%31.63%24.67% NKGen Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NKGNNKGen BiotechN/A$0.31+6.8%N/A-89.1%$11.07M$80,000.00-0.06N/ADYAIDyadic International2.513 of 5 stars$1.49+22.1%$6.00+302.7%-17.7%$44.09M$2.90M-6.487Analyst RevisionHigh Trading VolumeGANXGain Therapeutics2.4867 of 5 stars$1.66-3.5%$7.33+341.8%-39.0%$44.03M$50,000.00-1.5120News CoverageGap DownACHLAchilles Therapeutics2.3832 of 5 stars$1.07+1.9%$4.00+273.8%+32.1%$43.98MN/A-0.65250AFMDAffimed3.5267 of 5 stars$2.72-9.3%$16.00+488.2%-42.7%$43.79M$8.95M0.0076Analyst ForecastBLRXBioLineRx1.9598 of 5 stars$0.55+1.9%$21.00+3,751.8%-67.9%$43.58M$17.05M-1.2140News CoverageATNMActinium Pharmaceuticals1.3025 of 5 stars$1.39-2.1%$7.40+432.4%N/A$43.36M$81,000.00-1.0049Analyst ForecastOCXOncoCyte1.4506 of 5 stars$2.75+7.8%$4.42+60.6%-32.8%$42.93M$1.50M0.00120Analyst ForecastRVPHReviva Pharmaceuticals2.622 of 5 stars$1.22-3.2%$15.50+1,175.7%-71.1%$42.14MN/A0.005OMGAOmega Therapeutics1.7995 of 5 stars$0.79+3.9%$9.20+1,064.3%-60.5%$42.08M$3.09M0.00120VRCAVerrica Pharmaceuticals4.575 of 5 stars$0.89flat$9.60+981.8%-76.1%$40.58M$5.12M0.0040News Coverage Related Companies and Tools Related Companies Dyadic International Alternatives Gain Therapeutics Alternatives Achilles Therapeutics Alternatives Affimed Alternatives BioLineRx Alternatives Actinium Pharmaceuticals Alternatives OncoCyte Alternatives Reviva Pharmaceuticals Alternatives Omega Therapeutics Alternatives Verrica Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:NKGN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NKGen Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NKGen Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
